CDNACareDx, Inc.
Is the price fair?
A demanding price: priced for +25% a year vs +14% a year delivered and rich vs its sector.
Priced for ~25% a year FCF growth. The price demands more than its three-year revenue growth of 14% a year, priced for acceleration.
Sector median 25.1× across 135 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.
All from derived, as of Jun 30, 2026.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What CDNA's price assumes
CareDx, Inc. trades at 33.4× earnings against 36.7× for the median Diagnostics & Research name, cheaper than its own group.
Trailing P/E · Diagnostics & Research median 36.7 · cheaper than the typical name in its group
- Price / sales
- 7.81
Price / sales · today's price, trailing year to Jun 30, 2026
- Free cash flow yield
- 1.1%
Free cash flow yield · Diagnostics & Research median 2.9%
- Growth the price implies
- +25%
Growth the price implies · The price pays for +25% free cash flow growth a year for a decade; revenue has grown 14% a year over the last three.
Details›
- Price / booktoday's price, trailing year to Jun 30, 2026
- 8.41
- EV / EBITtoday's price, trailing year to Jun 30, 2026
- 31.5
- EV / salestoday's price, trailing year to Jun 30, 2026
- 7.43
- Healthcare median P/E503 names
- 27.9
- Diagnostics & Research median P/E33 names
- 36.7
- Free cash flow, trailing twelve months
- $41M
- Market capitalisation51.7 million shares, counted Jul 27, 2026
- $3.58B
- 3-year revenue growth
- +14%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
What is it worth?
Today's price against what its own multiples, its cash flow and your growth assumption say it is worth.
Against its own past
Its multiples now against their own history, and how much of the price move came from earnings rather than the multiple.
Diagnostics & Research
Ranks #6 of 21 by RyuScore